463 related articles for article (PubMed ID: 3877518)
1. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
[TBL] [Abstract][Full Text] [Related]
2. Altered behaviour of erythrocytes in scleroderma.
Kovacs IB; Sowemimo-Coker SO; Kirby JD; Turner P
Clin Sci (Lond); 1983 Nov; 65(5):515-9. PubMed ID: 6617097
[TBL] [Abstract][Full Text] [Related]
3. [Erythrocyte filterability in Raynaud's disease].
Sciannameo F; Francucci M; Cao PG; Marianeschi P; Valentini M; Tockner M; Sassano L; Grasselli A
Ric Clin Lab; 1983; 13 Suppl 3():475-80. PubMed ID: 6673030
[TBL] [Abstract][Full Text] [Related]
4. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
[TBL] [Abstract][Full Text] [Related]
5. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.
Dowd PM; Kovacs IB; Bland CJ; Kirby JD
Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326
[No Abstract] [Full Text] [Related]
6. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
7. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome.
Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P
Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252
[No Abstract] [Full Text] [Related]
8. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon.
Seibold JR; Harris JN
J Rheumatol; 1985 Feb; 12(1):99-103. PubMed ID: 2580093
[TBL] [Abstract][Full Text] [Related]
9. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon.
Biondi ML; Marasini B; Bianchi E; Agostoni A
Int J Cardiol; 1988 Jun; 19(3):335-9. PubMed ID: 3397197
[TBL] [Abstract][Full Text] [Related]
10. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
[TBL] [Abstract][Full Text] [Related]
11. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
12. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
13. Altered microrheological parameters in Raynaud's phenomenon.
Papp J; Sandor B; Toth A; Biro K; Rabai M; Botor D; Kovacs D; Csernus Z; Toth K; Kesmarky G
Clin Hemorheol Microcirc; 2017; 65(1):23-29. PubMed ID: 27258205
[TBL] [Abstract][Full Text] [Related]
14. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.
Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J
Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149
[TBL] [Abstract][Full Text] [Related]
15. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
Kahan A; Amor B; Menkes CJ
Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
[TBL] [Abstract][Full Text] [Related]
16. [Hemorrheology and neurovascular syndromes of the extremities].
Sergio G; Artale F; Francisci A; Giunti P; Perego MA
Ric Clin Lab; 1983; 13 Suppl 3():481-5. PubMed ID: 6673031
[TBL] [Abstract][Full Text] [Related]
17. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis.
Bukhari M; Herrick AL; Moore T; Manning J; Jayson MI
Br J Rheumatol; 1996 Nov; 35(11):1127-31. PubMed ID: 8948300
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous microcirculation in systemic sclerosis and response to intra-arterial reserpine.
Nilsen KH; Jayson MI
Br Med J; 1980 Jun; 280(6229):1408-11. PubMed ID: 7427134
[TBL] [Abstract][Full Text] [Related]
19. Calcium influx into red blood cells: the effect of sera from patients with systemic sclerosis.
Rademaker M; Thomas RH; Kirby JD; Kovacs IB
Clin Exp Rheumatol; 1991; 9(3):247-51. PubMed ID: 1879084
[TBL] [Abstract][Full Text] [Related]
20. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
Hostein J; Bost R; Carpentier P; Franco A; Fournet J
Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
